A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection

Respiratory syncytial virus (RSV) causes a respiratory disease with a potentially fatal outcome especially in infants and elderly individuals. Several vaccines failed in pivotal clinical trials, and to date, no vaccine against RSV has been licensed. We have developed an RSV vaccine based on the reco...

Descripción completa

Detalles Bibliográficos
Autores principales: Endt, Kathrin, Wollmann, Yvonne, Haug, Jana, Bernig, Constanze, Feigl, Markus, Heiseke, Alexander, Kalla, Markus, Hochrein, Hubertus, Suter, Mark, Chaplin, Paul, Volkmann, Ariane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238321/
https://www.ncbi.nlm.nih.gov/pubmed/35774800
http://dx.doi.org/10.3389/fimmu.2022.841471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238321/
https://www.ncbi.nlm.nih.gov/pubmed/35774800
http://dx.doi.org/10.3389/fimmu.2022.841471

Ejemplares similares